Wuxi apptec has invested 120 million US dollars to build an integrated R & D Service Center for Biopharmaceutics in Shanghai, accelerating the R & D process of global Biopharmaceutics from innovative ideas to clinical practice

ink="http://lianghui.china.com.cn/rollnews/2010-08/25/content_3969969.htm" src="http://" class="lazy" original="http://" alt="" />
Wuxi apptec announced the construction of the world's leading integrated research and Development Service Center for biopharmaceuticals in the company's Shanghai headquarters park, aiming to provide integrated solutions for global biopharmaceutical discovery, development and clinical production, and provide one-stop services for promoting biopharmaceutical research and development from innovative ideas to clinical practice The total investment of the center project is planned to be 120 million US dollars, covering an area of 250000 square feet After completion, it can accommodate 800 scientists The new center is expected to be completed and put into operation in 2017 The R & D service center of Wuxi Wuxi Pharmaceutical Co., Ltd is composed of the discovery center, development center and cGMP clinical sample base The center for discovery of biological drugs will cooperate with OMT (open Mo noclonal Technology) Co., Ltd of the United States through omnirat, an advanced all human monoclonal antibody platform of OMT Gamma As well as the unique phage display library of Wuxi apptec, it helps customers around the world to develop conventional monoclonal antibodies, bispecific monoclonal antibodies and antibody coupled drugs The bio pharmaceutical development center adopts the CHO cell line platform with independent intellectual property rights of Wuxi Pharmaceutical Co., Ltd., and its advanced flow adding and perfusion processes can meet all kinds of severe process needs The cGMP clinical sample base will install 3 disposable bioreactors with 2000 liter process and 2 500 liter perfusion process, which can prepare 4 clinical samples at the same time Through the integration of the demand for discovery, development and sample preparation of biopharmaceuticals, the new R & D Service Center will provide more high-quality, efficient, fast and flexible services for the R & D of innovative biopharmaceuticals for the global customers of Wuxi apptec "The continuous investment of Wuxi apptec in the R & D capacity of biopharmaceuticals will better support the fast-growing R & D business demand of our global customers," said Dr Li Ge, chairman and chief executive officer of Wuxi apptec "The completion of the new center will further strengthen the leading position of Wuxi apptec in the R & D service field of biopharmaceuticals, and provide unique and integrated services for our global customers Innovative R & D solutions "